Halozyme Therapeutics, Inc. — Biotechnology. Scored on the same transparent 7-signal model behind the daily rankings.
★
HALO
Halozyme Therapeutics, Inc. · Biotechnology
FCF$668mC+
Rev+37.6%A
D/E9.91D
P/E27.6xB
PEG0.73A-
81.6Score
$78.62$9.3B
1Y Target$83.90Analyst consensus · 10 analysts
5Y Target$105.92Compound horizon
10Y Target$135.84Long-dated conviction
FCF$668mTTMC+
FCF $668m — respectable but not differentiating
Rev+37.6%TTM YoYA
Revenue +37.6% — hypergrowth, top decile
D/E9.91D
D/E 9.91 — most levered decile in Healthcare (≈95th pctile)
P/E27.6xB
P/E 27.6 — near the Healthcare median (≈60th pctile)
PEG0.73proxyA-
PEG 0.73 — strong; Lynch's preferred zone · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 81.6
Quality0.81
Growth1.00
Value0.67
Why this score
Buying back stock
Durable high returns
Entry · Margin of safety
52-week rangeNear 52-week high
4% off the 12-month high
vs DCF fair value45% belowest. fair value ~$142
Quality signals · context only
Gross profitability47% · A-gross profit ÷ total assets (Novy-Marx)
ROIC17.1% · A-return on invested capital — not score-weighted
Why now
Halozyme Therapeutics is a compelling growth story, leveraging its patented recombinant human hyaluronidase enzyme (rHuPH20) to enable more efficient subcutaneous delivery of injectable biologics. This unique technology underpins its impressive 37.6% FY YoY revenue growth and robust 23.1% profit margin, while a 0.76 PEG ratio suggests the market has yet to fully price in its compounding potential. The crux of the thesis rests on the continued adoption of its rHuPH20 platform as a standard for enhancing drug dispersion and absorption, driving sustained demand for its proprietary enzymes and devices.
Moat
Halozyme's durable edge stems directly from its patented recombinant human hyaluronidase enzyme (rHuPH20) technology, which is critical for enabling the subcutaneous administration of complex biologics. This proprietary enzyme, foundational to products like Hylenex recombinant, creates significant switching costs for pharmaceutical partners who integrate it into their drug delivery systems. The specialized nature of developing and commercializing such enzymes for enhanced dispersion and absorption establishes a high barrier to entry, protecting its market position.
Risk
The primary bear case for Halozyme centers on its significant reliance on the patented rHuPH20 enzyme platform, which faces potential long-term risks from emerging alternative drug delivery technologies or competing enzyme formulations. While currently growing rapidly, a P/E (TTM) of 28.6 leaves little room for error if revenue growth decelerates from its current pace. A sustained slowdown in new licensing agreements for its rHuPH20 technology or a significant decline in the adoption rate of its SC administration solutions would confirm the bear case and challenge its premium valuation.
Horizon
1-3 yr $83.90 (10-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $105.92 at ~6% CAGR — dividend + buyback compounding. 10 yr $135.84 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · HALO
$
%
%
Shares to buy
25
Position size
$1,966
3.9% of portfolio
Stop price
$58.97
25% below $78.62
$ at risk if stopped
$491.38
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Halozyme Therapeutics, Inc. (HALO): score, valuation & FAQ
Halozyme Therapeutics, Inc. (HALO) is a Biotechnology company that scores 81.6 out of 100 on the Bull Rankings quality-growth model — a strong reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A) and PEG (A-), while D/E (D) rate weaker. On valuation, HALO sits about 45% below our discounted-cash-flow fair value (a margin of safety).
Is HALO a good stock to buy?
Bull Rankings scores HALO 81.6 out of 100 on its quality-growth model, which is a strong reading. That is driven by Rev (A) and PEG (A-). A score is a quantitative screen of Halozyme Therapeutics, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does HALO score 81.6 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). HALO earns its highest marks on Rev (A) and PEG (A-), and is held back by D/E (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is HALO overvalued or undervalued?
Based on $78.62, HALO sits about 45% below our discounted-cash-flow fair value (a margin of safety). It trades at a 27.6x× P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in HALO?
The primary bear case for Halozyme centers on its significant reliance on the patented rHuPH20 enzyme platform, which faces potential long-term risks from emerging alternative drug delivery technologies or competing enzyme formulations. While currently growing rapidly, a P/E (TTM) of 28.6 leaves little room for error if revenue growth decelerates from its current pace. A sustained slowdown in new licensing agreements for its rHuPH20 technology or a significant decline in the adoption rate of its SC administration solutions would confirm the bear case and challenge its premium valuation.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.